



PolyNovo Limited  
ABN 96 083 866 862  
2/320 Lorimer Street  
Port Melbourne  
VIC Australia 3207  
P +61 (0) 3 8681 4050

16 May 2025

## ASX Announcement

### May 2025 Investor Update Webcast Recording

For shareholders and other interested parties who were unable to attend the Investor Update Webcast live, or would like the opportunity to view it again, the recording can be viewed at the link below.

<https://vimeo.com/1084856728/6e8775b523>

This announcement has been authorised by PolyNovo Company Secretary, Jan Gielen.

#### About PolyNovo®

PolyNovo is a disruptive medical technology company, headquartered in Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. The Company has treated 70,000+ patients in 46 countries and is investing for growth via new products, indications, and markets. For more information see [polynovo.com](http://polynovo.com).

#### About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.